Topic 397 - microfluidic vortex shedding: a low-cost, high efficiency method for genetic modification to support cell engineering for cell-based immunotherapies
Ended Definitive Contract Awarded Last action
- Contract number
- 75N91020C00030
- Awardee
-
Indee. Inc. UEI SMXHTLFW8M47
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $399,299
Award facts
- Opportunity
-
- A solicitation of the national institutes of health (NIH) and the centers for disease control and prevention (CDC) for small business innovation research (SBIR) contract proposals Solicitation · PHS20201 · Posted Jun 21, 2019
- Contract value 100% obligated
- $399,299.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 6 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Berkeley, CA 94710, USA
- Research
- SBIR Program Phase I Action
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Original award | $399,299 |
About this award
This SBIR Phase I contract from the National Institutes of Health's National Cancer Institute was awarded to Indee Inc., doing business as Indee Inc., located in Albany, California. The firm fixed price contract valued at $399,299 will support research and development of microfluidic vortex shedding as a low-cost, high-efficiency method for genetic modification to support cell engineering for cell-based immunotherapies. The contract was awarded under a total small business set-aside solicitation seeking proposals for Phase I and Phase II SBIR contracts to conduct R&D in support of NIH and CDC agency missions, including alternatives to cell culture materials and cancer immunotherapy manufacturing. Indee Inc. will perform the work over a one-year period ending in September 2021 at its Albany facility.
Quick answers
Who was awarded contract 75N91020C00030?
75N91020C00030 was awarded to Indee. Inc. by National Cancer Institute (National Institutes of Health) on September 8, 2020.
How much is contract 75N91020C00030 worth?
The government has obligated $399,299 on 75N91020C00030.
Was contract 75N91020C00030 competed?
The extent of competition for 75N91020C00030 was full and open competition after exclusion of sources. The government received 6 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award